Heart Failure July 22, 2026

How Earlier Hemodynamic Insight May Help Guide Heart Failure Management July 22, 2026

Heart failure continues to place a significant burden on patients and the healthcare system, with nearly 7 million Americans living with heart failure, with prevalence expected to reach nearly 9 million by 2030. Despite advances in guideline-directed medical therapy (GDMT), many patients still face high risks of hospitalization, mortality, and reduced quality of life.

Cardiology Pharmaceuticals July 20, 2026

An Oral PCSK9i and What it Means for Merck July 20, 2026

PCSK9 inhibitors are some of the most effective LDL-lowering drugs out there, but they’ve all required injection, and some even refrigeration. That just changed, however, with the FDA’s approval of Merck's Lipfendra (enlicitide), the first ever oral PCSK9i.

Cardiology Pharmaceuticals July 17, 2026

Can Kerendia Handle the (Blood) Pressure? More Findings from FINEARTS-HF. July 17, 2026

One year after its FDA approval for HF treatment, a new FINEARTS-HF substudy shows Bayer’s Kerendia (finerenone) isn’t just impervious to BP differences, it could actually give a small leg up to patients with hypertension.

Cardiac Imaging July 16, 2026

Zero CAC And The Cost of CCTA-QPA July 16, 2026

The power of a zero CAC score is facing fresh scrutiny after new plaque analysis data presented at SCCT 2026 shows just how much noncalcified plaque confers its own cardiovascular risk, despite the software’s financial barriers.

More Stories

Heart Failure July 9, 2026

POLY-HF and the Possibility of HF Polypills July 9, 2026

Guideline-directed heart failure therapy works, but the biggest hurdle is getting patients to actually take it and fresh results in Nature from the POLY-HF trial suggest a polypill approach could be the answer.

Artificial Intelligence July 2, 2026

DETECT AS II and the Importance of Assertive Notifications July 2, 2026

We already know that passive EHR alerts improve severe aortic stenosis management, but the DETECT AS II study now suggests a more forceful “opt-out” approach could substantially increase how many patients get timely valve replacement.

Heart Failure July 2, 2026

Uncertainty Lingers on VNS for HF After Shortened Study July 2, 2026

Freshly published data from LivaNova’s pivotal ANTHEM-HFrEF trial hinted that vagal nerve stimulation might help patients with HFrEF, but the company's early termination decision left some questions unanswered.

Structural Heart June 29, 2026

EARLY TAVR 5-Year Data Answer Some Questions, Raise Others June 29, 2026

Whether or not to intervene early in asymptomatic aortic stenosis was answered by EARLY TAVR in 2024, and new 5-year data presented at NYV 2026 now suggests that the benefit of early intervention is driven by reductions in death and stroke rather than just heart failure.

Cardiology Practices June 25, 2026

APPs are Growing in Compensation and Relevance in Cardiology June 25, 2026

Advanced practice providers have long been viewed as support staff in cardiology, but MedAxiom's new 2025 APP Compensation and Utilization Report suggests they've moved well beyond that role.

Heart Failure June 22, 2026

Heart Failure GDMT Reduces Hospitalizations and Financial Burden June 22, 2026

The four-drug guidelines for heart failure with reduced ejection fraction are well established to cut hospitalizations and a new economic analysis in JAMA suggests that the hospital cost-savings more than cover the cost of the drugs themselves.

Get twice-weekly insights on the biggest stories shaping cardiology.